Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockage

Our aim was to describe the incidence and characteristics of immune-related adverse events (irAEs) in patients with non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI) and to evaluate their impact on outcome. All cases of NSCLC patients treated with ICIs in the second-...

Full description

Saved in:
Bibliographic Details
Published in:Journal of chemotherapy (Florence) 2021-02, Vol.33 (1), p.32-39
Main Authors: Conde-Estévez, David, Monge-Escartín, Inés, Ríos-Hoyo, Alejandro, Monzonis, Xavier, Echeverría-Esnal, Daniel, Moliner, Laura, Duran-Jordà, Xavier, Taus, Álvaro, Arriola, Edurne
Format: Article
Language:English
Subjects:
adverse events
atezolizumab
Immunotherapy
lung neoplasm
nivolumab
pembrolizumab
survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Our aim was to describe the incidence and characteristics of immune-related adverse events (irAEs) in patients with non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI) and to evaluate their impact on outcome. All cases of NSCLC patients treated with ICIs in the second-line setting between December 2015 and May 2018 were evaluated. Seventy patients were included. Mean age was 65.9 years, and the majority of male (n = 53, 75.7%), with PS of 0-1 (n = 62, 88.6%) treated with nivolumab (n = 51; 72.9%). Thirty-one patients (44.3%) experienced an AE, 5 (7.1%) were grades 3-4. Median OS in patients with AE was 30.1 months (95% CI, 16.7-43.5) compared with 5.1 months (95% CI, 1.2-9.0) in cases without AE (log-rank test: p = 0.010). The adjusted HR for OS was 0.46 (95% CI, 0.25-0.86) for the irAE occurrence and 3.60 (95% CI, 1.56-8.32) for PS 2-3 group. The development of irAEs was associated with improved patient outcome.
ISSN:1120-009X
1973-9478
DOI:10.1080/1120009X.2020.1849488